Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, July 24, 2017
[ Mon, Jul 24th 2017
] - WOPRAI
Fri, July 21, 2017
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
[ Fri, Jul 21st 2017
] - WOPRAI
David Toung Maintained (ABT) at Strong Buy with Increased Target to $62 on, Jul 21st, 2017
David Toung of Argus Research, Maintained "Abbott Laboratories" (ABT) at Strong Buy with Increased Target from $55 to $62 on, Jul 21st, 2017.
David has made no other calls on ABT in the last 4 months.
There are 3 other peers that have a rating on ABT. Out of the 3 peers that are also analyzing ABT, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Lewis of "Morgan Stanley" Maintained at Hold with Increased Target to $49 on, Monday, July 10th, 2017
- Isaac Ro of "Goldman Sachs" Initiated at Hold and Held Target at $45 on, Tuesday, May 16th, 2017
This is the rating of the analyst that currently disagrees with David
- Christopher Pasquale of "Guggenheim" Initiated at Strong Buy and Held Target at $58 on, Thursday, June 29th, 2017
Similar Stocks and Investing Articles
[ Thu, Jul 20th 2017
] - WOPRAI
[ Mon, Jul 17th 2017
] - WOPRAI
[ Wed, Jul 12th 2017
] - WOPRAI
[ Mon, Jul 10th 2017
] - WOPRAI
[ Tue, Aug 23rd 2016
] - WOPRAI
[ Tue, Aug 16th 2016
] - WOPRAI
[ Fri, Jul 29th 2016
] - WOPRAI
[ Thu, Jul 07th 2016
] - WOPRAI
[ Fri, Jul 25th 2014
] - WOPRAI